Echo IQ Ltd (ASX: EIQ) Share Price and News
Price
$0.225
Movement
0.00 (0.0)
as at 13 Jun - Closed (20 mins delayed)
52 Week Range
$0.14 - $0.37
1 Year Return
+36.36%
Echo IQ Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$145.17 million
P/E Ratio
N/A
Dividend Yield
0.00%
Shares Outstanding
645.19 million
Earnings per share
-0.017
Dividend per share
N/A
Year To Date Return
-2.17%
Earnings Yield
N/A
Franking
-
Share Price
$0.225
Day Change
0.00 (0.0)
52 Week Range
$0.14 - $0.37
Yesterday's Close
$0.225
Today's Open
–
Days Range
– - –
Volume
0
Avg. Volume (1 month)
3,529,645
Turnover
$0
as at 13 Jun - Closed
Echo IQ Ltd (ASX: EIQ)
Latest News
Share Gainers
Guess which ASX biotech stock just rocketed 25% on big US news
EIQ ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|
About Echo IQ Ltd
EchoIQ Ltd. engages in the development, marketing and commercialization of software, products and services. It develops and patents algorithm dealing in Prescriptive Analytics. The company was founded by Richard Charles Anstey on March 31, 2010 and is headquartered in Sydney, Australia.
EIQ Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 11 Jun 2025 | $0.22 | $-0.01 | -4.44% | 2,228,420 | $0.22 | $0.23 | $0.22 |
| 10 Jun 2025 | $0.23 | $0.00 | 0.00% | 2,650,963 | $0.22 | $0.23 | $0.22 |
| 06 Jun 2025 | $0.23 | $0.01 | 4.55% | 1,737,885 | $0.23 | $0.24 | $0.22 |
| 05 Jun 2025 | $0.22 | $-0.01 | -4.35% | 1,202,844 | $0.23 | $0.23 | $0.22 |
| 04 Jun 2025 | $0.23 | $0.01 | 4.44% | 751,552 | $0.24 | $0.24 | $0.22 |
| 03 Jun 2025 | $0.23 | $-0.01 | -4.35% | 2,092,961 | $0.23 | $0.23 | $0.22 |
| 02 Jun 2025 | $0.23 | $-0.02 | -8.16% | 2,870,724 | $0.24 | $0.24 | $0.22 |
| 30 May 2025 | $0.25 | $-0.01 | -4.00% | 1,907,683 | $0.26 | $0.26 | $0.24 |
| 29 May 2025 | $0.25 | $0.00 | 0.00% | 2,109,915 | $0.26 | $0.26 | $0.25 |
| 28 May 2025 | $0.25 | $-0.02 | -7.41% | 2,645,462 | $0.27 | $0.27 | $0.25 |
| 27 May 2025 | $0.27 | $-0.01 | -3.64% | 2,036,435 | $0.28 | $0.28 | $0.27 |
| 26 May 2025 | $0.28 | $-0.01 | -3.57% | 2,246,453 | $0.29 | $0.29 | $0.27 |
| 23 May 2025 | $0.28 | $0.01 | 3.70% | 3,622,487 | $0.27 | $0.29 | $0.27 |
| 22 May 2025 | $0.27 | $0.01 | 3.77% | 5,000,453 | $0.27 | $0.28 | $0.26 |
| 21 May 2025 | $0.27 | $0.03 | 12.50% | 14,256,407 | $0.27 | $0.29 | $0.26 |
| 19 May 2025 | $0.24 | $-0.08 | -25.00% | 14,616,153 | $0.32 | $0.32 | $0.22 |
| 16 May 2025 | $0.32 | $0.02 | 6.67% | 3,434,308 | $0.31 | $0.33 | $0.30 |
| 15 May 2025 | $0.30 | $0.00 | 0.00% | 1,141,628 | $0.30 | $0.31 | $0.30 |
| 14 May 2025 | $0.30 | $0.00 | 0.00% | 5,498,037 | $0.30 | $0.31 | $0.30 |
| 13 May 2025 | $0.30 | $-0.01 | -3.28% | 4,951,070 | $0.31 | $0.31 | $0.30 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 04 Mar 2025 | Ken Nelson | Issued | 4,000,000 | $40 |
Issue of options.
|
| 17 Dec 2024 | Steven Formica | Expiry | 8,800,000 | $1,980,000 |
Options expired.
|
| 17 Dec 2024 | Andrew Grover | Expiry | 11,800,000 | $2,655,000 |
Options expired.
|
| 29 Oct 2024 | Stephen (Steve) Picton | Expiry | 2,000,000 | $450,000 |
Options expired.
|
| 28 Jun 2024 | Simon Tolhurst | Buy | 7,100,000 | $3 |
Off-market trade.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Mr Stephen (Steve) Picton | Non-Executive Director | Oct 2021 |
Mr Picton has over 35 years of experience in the technology industry having held senior positions in British Telecom (BT) and AAPT prior to him forming gotalk and relaunching LBNCo.
|
| Mr Steven Allen Formica | Non-Executive Director | Jul 2018 |
Mr Formica brings to the Group practical management and business development experience. He has been a businessman and operations manager for over 31 years in several privately held business ventures including manufacturing, construction, landscape contracting, property development and integrated wholesale and retail businesses.
|
| Mr Andrew Grover | Executive ChairmanExecutive Director | May 2019 |
Mr Grover has 26 years of experience in management, business development, sales & marketing, administration and technology across a diverse range of industries. As a founder and investor in numerous innovative companies, Andrew's businesses have been featured in BRW Fast 100 and Deloitte's Fast 50 over several years.
|
| Mr Ken Nelson | Non-Executive Director | Dec 2024 |
Mr Ken Nelson is a leading US-based medical technology and healthcare executive with over 20 years industry experience. During his career he has been pivotal in leading successful commercialisation efforts with multiple cardiac-focused digital health companies including remote cardiac and diagnostics monitoring business, BioTelemetry, wearable device company, iRhythm and ambulatory ECG solutions monitoring group, Bardy Diagnostics.
Currently, he serves as partner in the Medtech Advantage Fund, which has an exclusive partnership with Medtech Innovator (www.medtechinnovator.org), the largest medical technology and digital health startup accelerator globally. In addition to this, Mr Nelson serves as Chairman to the Board of Israeli-based medical technology company, CardiaCare, and is an active Board member of other cardiac-focused digital health and medical technology companies including HeartBeam (NASDAQ: BEAT), Acarix (NASDAQ: ACARIX), US-based company Epitel, and European-based platform Happitech. Mr Nelson also sits on a number of advisory boards and planning committees for early-stage medical technology companies, as well as several industry groups including the Innovation Advisory Board of Heart Rhythm Society, the Health Tech Innovation Business Advisory Board and the Heart & Brain Accelerator of the American Heart Association. |
| Ms Jessamyn Sarah Lyons | Company Secretary | Oct 2021 |
-
|
| Mr Dustin Haines | Chief Executive Officer | Jan 2025 |
-
|
| Deon Strydom | Chief Commercial Officer |
-
|
|
| Dustin Haines | Chief Executive Officer |
-
|
|
| Prof. David Playford | Chief Medical Advisor |
-
|
|
| Philip Woolff | Chief Operating Officer |
-
|
|
| Prof. Geoff Strange | Chief Research & Strategy Officer |
-
|
|
| Sean Bryceland | Chief Technology Officer |
-
|
|
| Jessamyn Sarah Lyons | Company Secretary |
-
|
|
| Dane Brescacin | VP Regulatory Affairs |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| J P Morgan Nominees Australia Pty Limited | 33,199,295 | 5.64% |
| A22 Pty Ltd | 28,500,000 | 4.84% |
| Stevsand Investments Pty Ltd <Steven Formica Family A/C> | 27,100,000 | 4.60% |
| Richmond Bridge Superannuation Pty Ltd <Richmond Bridge Super A/C> | 21,764,854 | 3.70% |
| Alerte Digital Health Pte Ltd | 17,373,863 | 2.95% |
| Bellcoo Investments Pty Ltd < The Northlake S/F A/C> | 15,248,099 | 2.59% |
| Mr Brian Joseph Glynn | 13,875,483 | 2.36% |
| King Corporate Pty Ltd | 13,283,334 | 2.26% |
| Shah Nominees Pty Ltd <Louis Carsten Super Fund A/C> | 12,700,000 | 2.16% |
| Heath Nominees (Aust) Pty Ltd < The Heath Family A/C> | 12,361,373 | 2.10% |
| Shah Nominees Pty Ltd | 10,060,162 | 1.71% |
| BNP Paribas Noms Pty Ltd <Global Markets> | 9,952,397 | 1.69% |
| Hunt Prosperity Pty Ltd <Investius Pb Micro Cap A/C> | 9,803,001 | 1.67% |
| Belgravia Strategic Equities Pty Ltd | 8,526,000 | 1.45% |
| Ms Laura Bailey | 8,250,000 | 1.40% |
| T Mitchell Pty Ltd < The T Mitchell S/F A/C> | 7,668,236 | 1.30% |
| Shriver Nominees Pty Ltd | 7,150,000 | 1.21% |
| Kli Pty Ltd <The T Teh'S Family A/C> | 6,840,000 | 1.16% |
| Xeryus International Pty Ltd | 6,590,481 | 1.12% |
| Mikado Corporation Pty Ltd <Jfc Superannuation A/C> | 6,300,000 | 1.07% |